Researchers found that the percentage of clinical pregnancy in the NAC group was 33 percent compared to 10 percent for the control group
The injectable weight-loss drug Wegovy is the only medication currently approved for cardiovascular indications in patients with overweight or obesity and existing cardiovascular disease
Enter: electrolyte drinks
Meet our doctors Last reviewed: 19 Jun 2026 Sources Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity, Diabetes, Obesity and Metabolism, [accessed 14 January 2026] Transdermal drug delivery: overcoming the skin's barrier function, Europe PMC [accessed 14 January 2026] (D) Routes of delivery: Case studies: (6) Transdermal delivery of peptides and proteins, Advanced Drug Delivery Reviews, [accessed 14 January 2026] Semaglutide for the treatment of overweight and obesity: A review, Diabetes, Obesity and Metabolism, [accessed 14 January 2026] Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK, [accessed 14 January 2026]
Always consult your healthcare provider before making changes to your treatment regimen
